-
ABOUT US
Anhui Tongling Bionics Technology Ltd., established in July 2016 under the leadership of Professor Xie Qilian, a renowned cardiovascular specialist, is China's pioneering enterprise specializing in comprehensive heart failure management solutions encompassing diagnosis, treatment, and rehabilitation. The company holds the distinction of being the first equity-incubated entity of Advanced Technology Institute of the University of Science and Technology of China (USTC).
Our R&D engine is powered by a world-class innovation team, with core members hailing from globally-renowned institutions including Imperial College London, University of Maryland, Tsinghua University, University of Science and Technology of China, Chinese Academy of Sciences, Fuwai Hospital, Beijing Anzhen Hospital, etc.
Leveraging the resources of USTC Advanced Technology Institute and the National Health Big Data Industrial Park, we operates over 10,000 square meters of facilities for R&D, production, and office space in which includes nearly 2,000 square meters of specialized environments featuring ISO Class 5 cleanrooms, ISO Class 6 cleanrooms, and sterile laboratories.
We holds multiple prestigious credentials including National ‘Little Giant' Enterprise, National High-Tech Enterprise, National Intellectual Property Advantage Enterprise, National Postdoctoral Station, Anhui Artificial Heart Engineering Research Center, Key Laboratory of Bionics Medicine, and has a series of R&D projects under the national key research and development plan and many provincial and municipal plans.
Anchored in cardiopulmonary assistive technology breakthroughs, we pioneered China's first integrated development and manufacturing of percutaneous Ventricular Assist Device (pVAD), Intra-Aortic Balloon Pump (IABP), Enhanced External Counterpulsation (EECP)，and Non-invasive Cardiac Output Monitor (ICG), etc. We hold 400+ patents ensuring globally unique solutions for heart failure management.
Guided by our core values of "Integrity Compassion Innovation Excellence" and the mission "Integrated Heart Failure Lifecycle Solutions Provider", we will accelerate the research and application of core products, expand the Heart Failure Solution Ecosystem, holds the leading advantage in the specialized area。Meanwhile，we will follow closely the cutting-edge technologies to keep innovating，strive to become the global leader in bionic medical research and application development, and safeguard human health.
Foundation
R&D and Production Area
Global Patent
Honor
R&D Platforms
Foundation
R&D and Production Area
Global Patent
Honor
R&D Platforms
Anhui Tongling Bionics Technology Ltd.
WeChat official account
Anhui Tongling Bionics Technology Ltd.
Copyright © 2025 Anhui Tongling Bionics Technology Ltd.
Copyright © 2025 Anhui Tongling Bionics Technology Ltd.